Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax
Issued Date
2026-05-27
Resource Type
eISSN
14752875
Scopus ID
2-s2.0-105040640909
Pubmed ID
42204711
Journal Title
Malaria Journal
Volume
25
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Malaria Journal Vol.25 No.1 (2026)
Suggested Citation
Pasaribu A.P., Jimanto V., Ainur F., Saragih N.R., Hadi H., Siagian D.S.P., Sinaga B.J., Satyagraha A.W., Laihad F.J., Diptyanusa A., Ubra R.R., Tekege O., Darmayanti L., Herdiana H., Adella J., Mannion K., Curry E., Poespoprodjo J.R., Kenangalem E., Burdam F.H., Sutanto I., Nelwan E.J., Ganadhi G.J., Shrestha B., Mnjala H., Hawley W.A., Prameswari H.D., Theodora M., Silalahi F.S.M., Susanto H., Immanuella F., Puspadewi R.T., Fajariyani S.B., Samad I., Supriyanto D., Muhafilah N., Isa R., Price R.N., Thriemer K. Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax. Malaria Journal Vol.25 No.1 (2026). doi:10.1186/s12936-026-05948-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/117197
Title
Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax
Author(s)
Pasaribu A.P.
Jimanto V.
Ainur F.
Saragih N.R.
Hadi H.
Siagian D.S.P.
Sinaga B.J.
Satyagraha A.W.
Laihad F.J.
Diptyanusa A.
Ubra R.R.
Tekege O.
Darmayanti L.
Herdiana H.
Adella J.
Mannion K.
Curry E.
Poespoprodjo J.R.
Kenangalem E.
Burdam F.H.
Sutanto I.
Nelwan E.J.
Ganadhi G.J.
Shrestha B.
Mnjala H.
Hawley W.A.
Prameswari H.D.
Theodora M.
Silalahi F.S.M.
Susanto H.
Immanuella F.
Puspadewi R.T.
Fajariyani S.B.
Samad I.
Supriyanto D.
Muhafilah N.
Isa R.
Price R.N.
Thriemer K.
Jimanto V.
Ainur F.
Saragih N.R.
Hadi H.
Siagian D.S.P.
Sinaga B.J.
Satyagraha A.W.
Laihad F.J.
Diptyanusa A.
Ubra R.R.
Tekege O.
Darmayanti L.
Herdiana H.
Adella J.
Mannion K.
Curry E.
Poespoprodjo J.R.
Kenangalem E.
Burdam F.H.
Sutanto I.
Nelwan E.J.
Ganadhi G.J.
Shrestha B.
Mnjala H.
Hawley W.A.
Prameswari H.D.
Theodora M.
Silalahi F.S.M.
Susanto H.
Immanuella F.
Puspadewi R.T.
Fajariyani S.B.
Samad I.
Supriyanto D.
Muhafilah N.
Isa R.
Price R.N.
Thriemer K.
Author's Affiliation
Universitas Indonesia
Organisation Mondiale de la Santé
Universitas Gadjah Mada
Badan Riset dan Inovasi Nasional
Nuffield Department of Medicine
Universitas Sumatera Utara
Menzies School of Health Research
Mahidol Oxford Tropical Medicine Research Unit
Kementerian Kesehatan Republik Indonesia
Independent Consultant
Exeins Health Initiative
Lampung Provincial Health Office
Yayasan Pengembangan Kesehatan dan Masyarakat Papua
Health Office
District Health Office
Directorate of Vulnerable Group Health Services
Central Papua
Organisation Mondiale de la Santé
Universitas Gadjah Mada
Badan Riset dan Inovasi Nasional
Nuffield Department of Medicine
Universitas Sumatera Utara
Menzies School of Health Research
Mahidol Oxford Tropical Medicine Research Unit
Kementerian Kesehatan Republik Indonesia
Independent Consultant
Exeins Health Initiative
Lampung Provincial Health Office
Yayasan Pengembangan Kesehatan dan Masyarakat Papua
Health Office
District Health Office
Directorate of Vulnerable Group Health Services
Central Papua
Corresponding Author(s)
Other Contributor(s)
Abstract
The EFFORT clinical trial was conducted in four countries (Cambodia, Ethiopia, Indonesia, and Pakistan) to evaluate the safety and effectiveness of high-dose primaquine (7 mg/kg over 7 days) and single-dose tafenoquine (300 mg) compared with the standard 14-day low-dose primaquine regimen for the radical cure of patients with Plasmodium vivax malaria. In Indonesia, both regimens were co-administered with dihydroartemisinin-piperaquine. This paper reports on a national stakeholder meeting held in May 2025 to disseminate Indonesia-specific findings and discuss their implications for malaria control and elimination policy. Discussions centred on (i) the evidence gaps regarding tafenoquine when combined with artemisinin combination therapies (ACTs), (ii) the feasibility of implementing high-dose primaquine in Indonesia as a near-term option, and (iii) the need for subnational strategies that reflect the country's diverse epidemiological context. Stakeholders highlighted the need for further studies on tafenoquine with ACTs, while recognising high-dose primaquine as an immediately implementable option pending strengthened G6PD testing. The discussion emphasised the importance of tailoring strategies to Indonesia's diverse settings, supported by strong political commitment to elimination.